Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 4/20 | 0.58 |
| ▸ | TLR9 | Q9NR96 | 4/20 | 0.47 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.47 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.47 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.47 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | TDO2 | P48775 | 1/20 | 0.46 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1484608 | 0.87 | TNKS (0.59) | TNKSTLR9TLR8TLR7DGAT1 | |
| SCHEMBL1483712 | 0.87 | TNKS (0.59) | TNKSTLR9TLR8TLR7DGAT1 | |
| SCHEMBL13577842 | 0.86 | TNKS (0.58) | TNKSTLR9TLR8TLR7DGAT1 | |
| SCHEMBL1424190 | 0.86 | TNKS (0.58) | TNKSTLR9TLR8TLR7DGAT1 | |
| SCHEMBL1484021 | 0.84 | TNKS (0.56) | TNKSTLR9TLR8TLR7DGAT1 | |
| SCHEMBL1421333 | 0.83 | TNKS (0.55) | TNKSTLR9TLR8TLR7DGAT1 | |
| SCHEMBL1484208 | 0.80 | TNKS (0.59) | TNKSTLR9TLR8TLR7DGAT1 | |
| SCHEMBL13577843 | 0.79 | TNKS (0.58) | TNKSTLR9TLR8TLR7DGAT1 | |
| SCHEMBL1483676 | 0.79 | TNKS (0.58) | TNKSTLR9TLR8TLR7DGAT1 | |
| SCHEMBL1484023 | 0.77 | TNKS (0.56) | TNKSTLR9TLR8TLR7DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110076230-A1 | Novel Substituted Indoles | MERCK & CO. INC. | 2011-03-31 | — | — | US | claimed |
| EP-2296474-A1 | NOVEL SUBSTITUTED INDOLES | Merck Sharp & Dohme Corp. (US) | 2011-03-23 | — | — | EP | claimed |
| WO-2009155024-A1 | NOVEL SUBSTITUTED INDOLES | MERCK & CO., INC. (US) | 2009-12-23 | — | — | WO | claimed |
| US-20110076230-A1 | Novel Substituted Indoles | MERCK & CO. INC. | 2011-03-31 | — | — | US | disclosed |
| US-20110076230-A1 | Novel Substituted Indoles | MERCK & CO. INC. | 2011-03-31 | — | — | US | disclosed |
| US-20110076230-A1 | Novel Substituted Indoles | MERCK & CO. INC. | 2011-03-31 | — | — | US | disclosed |
| WO-2009155024-A1 | NOVEL SUBSTITUTED INDOLES | MERCK & CO., INC. (US) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110076230-A1 | Novel Substituted Indoles | APP, BACE1, PSEN1 | TNKS 3337/4885TLR9 4733/4885TLR8 4680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.